Abatacept (Orencia)
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy.
Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion.
It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied.
Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communication, absapt reduces inflammation.
Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion.
It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied.
Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communication, absapt reduces inflammation.
Comments
Post a Comment